

IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE DISTRICT OF DELAWARE

In re: ) Chapter 11  
)  
OREXIGEN THERAPEUTICS, INC., ) Case No. 18-10518 (KG)  
)  
Debtor.<sup>1</sup> )  
) Objection Deadline:  
) May 14, 2019 at 4:00 p.m. (EDT)


THIRTEENTH MONTHLY FEE STATEMENT OF HOGAN LOVELLS US LLP  
FOR PROFESSIONAL SERVICES AND DISBURSEMENTS AS CO-COUNSEL  
TO THE DEBTOR AND DEBTOR IN POSSESSION FOR THE  
PERIOD MARCH 1, 2019 THROUGH AND INCLUDING MARCH 31, 2019

NAME OF APPLICANT: Hogan Lovells US LLP (“Hogan Lovells”)  
ROLE IN CASE: Co-Counsel to the Debtor and Debtor in Possession  
DATE OF RETENTION: Order entered April 11, 2018 Authorizing Retention of  
Hogan Lovells *Nunc Pro Tunc* to March 12, 2018 (Docket  
No. 174)  
TIME PERIOD: March 1, 2019 through and including March 31, 2019  
CURRENT APPLICATION: Total Fees Requested: \$319,017.50  
80% of Fees Requested: \$255,214.00  
Total Expenses Requested: \$1,595.08  
Total Fees and Expenses Requested: \$320,612.58  
This is a X monthly \_\_\_ interim \_\_\_ final application

The total time expended to prepare this application was approximately 5.4 hours and the corresponding compensation requested will be approximately \$3,552.00<sup>2</sup>.

<sup>1</sup> The last four digits of the Debtor’s federal tax identification number are 8822. The Debtor’s mailing address for purposes of this Chapter 11 Case is Orexigen Therapeutics, Inc., c/o Hogan Lovells US LLP, 875 Third Avenue, New York, New York 10022, Attn: Chris Bryant and John Beck.

<sup>2</sup> Allowance for compensation for such time will be sought in subsequent fee applications.



If this is not the first application filed, disclose the following for each prior application:

<b>DATE FILED</b>	<b>PERIOD COVERED</b>	<b>REQUESTED FEES/EXPENSES</b>	<b>APPROVED FEES/EXPENSES</b>
5/11/18 D.I. 285	3/12/18-3/31/18	\$328,506.75/\$106.19	\$262,805.40/\$106.19 CNO filed 5/29/18 D.I. 334
6/5/18 D.I. 348	4/1/18-4/30/18	\$745,389.75/ \$3,507.83	\$596,311.80/\$3,507.83 CNO filed 6/20/18 D.I. 405
6/21/18 D.I. 407	5/1/18-5/31/18	\$220,308.25/ \$2,219.53	\$176,246.60/\$2,219.53 CNO filed 7/6/18 D.I. 473
8/3/18 D.I. 672	6/1/18 – 6/30/18	\$347,591.00/ 14,303.30	\$278,072.80/\$14,303.30 CNO filed 8/20/18 D.I. 694
8/27/18 D.I. 706	7/1/18-7/31/18	\$420,182.00/ \$6,949.67	\$336,145.60/\$6,949.67 CNO filed 9/13/18 D.I. 730
10/1/18 D.I. 762	8/1/18-8/31/18	\$136,960.00/ \$1,836.45	\$109,568.00/\$1,836.45 CNO filed 10/17/18 D.I. 787
10/30/18 D.I. 805	9/1/18-9/30/18	\$104,961.50/ \$1,525.34	\$83,969.20/\$1,525.34 CNO filed 11/15/18 D.I. 820
11/28/18 D.I. 832	10/1/18-10/31/18	\$127,684.00/ \$1,911.79	\$102,147.20/\$1,911.79 12/13/18 D.I. 850
12/17/18 D.I. 856	11/1/18-11/30/18	\$33,770.00/ \$1,079.07	\$27,016.00/\$1,079.07 1/2/19 D.I. 896

<b>DATE FILED</b>	<b>PERIOD COVERED</b>	<b>REQUESTED FEES/EXPENSES</b>	<b>APPROVED FEES/EXPENSES</b>
1/18/19 D.I. 930	12/1/18-12/31/18	\$45,253.00/\$437.39	\$36,202.40/\$437.39 CNO filed 2/5/19 D.I. 946
3/5/19 D.I. 961	1/1/19-1/31/19	\$180,802.50/\$927.42	\$144,642.00/\$927.42 CNO filed 3/20/19 D.I. 984
3/20/19 D.I. 976	2/1/19-2/28/19	\$156,360.50/\$409.03	\$125,088.40/\$409.03 CNO filed 4/11/19 D.I. 1043

Hogan Lovells US LLP  
Orexigen Therapeutics, Inc.  
Co-Counsel to Debtor and Debtor in Possession  
Chapter 11  
Timekeeper Chart  
March 1, 2019 through March 31, 2019

<b>Name of Professional Person</b>	<b>Position of the Applicant, Area of Expertise, Number of Years in that Position, Year Admitted to Bar.</b>	<b>Hourly Billing Rates</b>	<b>Total Hours</b>	<b>Total Compensation</b>
Christopher R. Donoho, III	Partner at Hogan Lovells since 2010. Joined Lovells LLP in 2007. Member of New York Bar since 1997. Areas of expertise: Business Restructuring and Insolvency	\$1,375.00	10.90	\$14,987.50
Pieter Van Tol	Partner at Hogan Lovells since 2010. Joined Hogan Lovells in 2010. Partner at Lovells, LLP since 2003. Member of the New York Bar since 1990. Areas of expertise: Litigation.	\$1,195.00	1.50	\$1,792.50
Scott Friedman	Partner at Hogan Lovells since 2010. Joined Hogan & Hartson as a Partner in 2002. Member of the New York Bar since 1986. Areas of expertise: Tax.	\$1,175.00	8.20	\$9,635.00
Christopher R. Bryant	Counsel at Hogan Lovells since 2014. Joined Hogan Lovells in 2010. Member of the New York Bar since 2001. Areas of expertise: Business Restructuring and Insolvency.	\$935.00	159.30	\$148,945.50
John D. Beck	Senior Associate at Hogan Lovells since 2014. Member of the New York Bar since 2011 and the Texas Bar since 2010. Areas of expertise: Business Restructuring and Insolvency.	\$895.00	67.90	\$60,770.50
Catherine Y. Chen	Associate at Hogan Lovells since 2015. Joined Hogan Lovells in 2015. Member of the New York Bar since 2016. Areas of expertise: Tax.	\$730.00	4.10	\$2,993.00
Eric L. Einhorn	Associate at Hogan Lovells since 2017. Joined Hogan Lovells in 2017. Member of the New York Bar since 2018. Areas of expertise: Business Restructuring and Insolvency.	\$590.00	81.20	\$47,908.00

<b>Name of Professional Person</b>	<b>Position of the Applicant, Area of Expertise, Number of Years in that Position, Year Admitted to Bar.</b>	<b>Hourly Billing Rates</b>	<b>Total Hours</b>	<b>Total Compensation</b>
Sean A. Feener	Associate at Hogan Lovells since 2017. Joined Hogan Lovells in 2017. Member of the New York Bar since 2018. Areas of expertise: Business Restructuring and Insolvency.	\$590.00	41.80	\$24,662.00
Jennifer Lee	Associate at Hogan Lovells since 2018. Joined Hogan Lovells in 2018. Member of the New York Bar since 2019. Areas of expertise: Business Restructuring and Insolvency.	\$530.00	6.40	\$3,392.00
Ronald Cappiello	Senior Paralegal at Hogan Lovells from 2013 to April 2019. Areas of expertise: Business Restructuring and Insolvency.	\$415.00	19.90	\$8,258.50
<b>Total Sub-total:</b>	<b>Chapter 11</b>		<b>401.20</b>	<b>\$323,344.50</b>
<b>Less 50% Discount-Non-Working Travel:</b>				<b>(\$4,327.00)</b>
<b>GRAND TOTAL:</b>				<b>\$319,017.50</b>
<b>BLENDED RATE: \$843.00</b>				

Hogan Lovells US LLP  
Orexigen Therapeutics, Inc.  
Co-Counsel to Debtor and Debtor in Possession  
Chapter 11  
PROJECT CATEGORY CHART  
March 1, 2019 through March 31, 2019

<b>Project Category</b>	<b>Total Hours</b>	<b>Total Fees</b>
<b>045803/Matter-000019-Chapter 11</b>		
03-Hearings	29.90	\$21,267.01
04- DIP or Exit Financing	1.10	\$1,028.50
05-Litigation: Contested Matters, Adv. Proceedings, other Litigation	27.10	\$19,776.50
07-Plan and Disclosure Statement	226.80	\$198,400.49
08-Claims Administration and Objections	51.80	\$38,320.50
10-Case Administration	7.60	\$5,215.50
17-Monthly Fee Statements and Interim/Final Fee Applications(Hogan Lovells)	20.20	\$10,063.00
20-Non-Working Travel	12.60	\$8,654.00
24-Asset Dispositions/363 Sales	2.20	\$2,057.00
25-Automatic Stay Matters	19.90	\$16,593.50
26-Insurance Matters	1.70	\$1,791.50
27-Vendor/Supplier Matters	0.30	\$177.00
<b>Total:</b>	<b>401.20</b>	<b>\$323,344.50</b>
<b>Less 50% discount-Non-Working Travel</b>	<b>----</b>	<b>(\$4,327.00)</b>
<b>GRAND TOTAL:</b>	<b>401.20</b>	<b>\$319,017.50</b>

Hogan Lovells US LLP  
 Orexigen Therapeutics, Inc.  
 Co-Counsel to Debtor and Debtor in Possession  
 Chapter 11  
 Expense Summary  
 March 1, 2019 through March 31, 2019

<b>Expense Category</b>	<b>Service Provider (if applicable)</b>	<b>Total Expenses</b>
Meals		\$44.40
Taxi		\$29.65
Car Service		\$322.94
Hospitality		\$40.05
Word Processing		\$168.75
Computer Research – Westlaw		\$957.29
EPIQ Other Case Specified Data Services		\$32.00
<b>Grand Total Expenses</b>		<b>\$1,595.08</b>

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE DISTRICT OF DELAWARE**

<b>In re:</b>  <b>OREXIGEN THERAPEUTICS, INC.,</b>  <div style="text-align: right;"><b>Debtor.<sup>1</sup></b> </div>	) ) ) ) ) ) )	<b>Chapter 11</b>  <b>Case No. 18-10518 (KG)</b>  <u><b>Objection Deadline:</b></u> <b>May 14, 2019 at 4:00 p.m. (EDT)</b>
---	---------------------------------	---

**THIRTEENTH MONTHLY FEE STATEMENT OF HOGAN LOVELLS US LLP  
FOR PROFESSIONAL SERVICES AND DISBURSEMENTS AS  
CO-COUNSEL TO THE DEBTOR AND DEBTOR IN POSSESSION FOR THE  
PERIOD MARCH 1, 2019 THROUGH AND INCLUDING MARCH 31, 2019**

Hogan Lovells US LLP (“**Hogan Lovells**”), as co-counsel to the Debtor and Debtor in Possession (the “**Debtor**”), hereby submits this application (the “**Fee Statement**”) for interim allowance of compensation for professional services rendered by Hogan Lovells to the Debtor for the period March 1, 2019 through and including March 31, 2019 (the “**Fee Statement Period**”) and reimbursement of actual and necessary expenses incurred by Hogan Lovells during the Fee Statement Period, pursuant to sections 330 and 331 of title 11 of the United States Code (the “**Bankruptcy Code**”), Rule 2016 of the Federal Rules of Bankruptcy Procedure (the “**Bankruptcy Rules**”), Rule 2016-2 of the Local Rules of Bankruptcy Practice and Procedure of the United States Bankruptcy Court for the District of Delaware (the “**Local Rules**”), the United States Trustee’s Guidelines for Reviewing Applications for Compensation and Reimbursement of Expenses filed under 11 U.S.C. § 330, effective January 30, 1996 (the “**U.S. Trustee Guidelines**”) and the Administrative Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals [Docket No. 171]

---

<sup>1</sup>The last four digits of the Debtor’s federal tax identification number are 8822. The Debtor’s mailing address for purposes of this Chapter 11 Case is Orexigen Therapeutics, Inc., c/o Hogan Lovells US LLP, 875 Third Avenue, New York, New York 10022, Attn: Chris Bryant and John Beck.



(the “**Compensation Order**”).<sup>2</sup> In support of this Fee Statement, Hogan Lovells respectfully represents as follows:

### **JURISDICTION**

1. This Court has jurisdiction over this Application pursuant to 28 U.S.C. §§ 157 and 1334. This is a core proceeding within the meaning of 28 U.S.C. § 157(b)(2). Venue in this district is proper pursuant to 28 U.S.C. §§ 1408 and 1409.

### **HOGAN LOVELLS’ RETENTION**

2. The Debtor engaged Hogan Lovells as its bankruptcy counsel on or about October 7, 2017 to prepare and execute this Chapter 11 Case. On March 23, 2018, the Debtor filed the *Application of the Debtor for Entry of an Order Pursuant To Bankruptcy Code Sections 327(a) 328, 330 and 1107 Authorizing Employment and Retention of Hogan Lovells US LLP as Counsel for the Debtor Nunc Pro Tunc to the Petition Date and Statement Required by Bankruptcy Code Section 329* [Docket No. 87] (the “**Retention Application**”).

3. On April 11, 2018, the Court granted the Retention Application pursuant to the *Order Granting the Application of the Debtor for Entry of an Order Pursuant to Bankruptcy Code Sections 327(a) 328, 330 and 1107 Authorizing Employment and Retention of Hogan Lovells US LLP as Bankruptcy Counsel for the Debtor Nunc Pro Tunc to the Petition Date* [Docket No. 174].

### **RELIEF REQUESTED**

4. During the Fee Statement Period, Hogan Lovells incurred actual, reasonable, and necessary fees in the amount of \$319,017.50. For the same period, Hogan Lovells incurred actual, reasonable, and necessary expenses totaling \$1,595.08. Pursuant to the Compensation

---

<sup>2</sup> Capitalized terms not defined herein are defined in the Compensation Order.

Order, Hogan Lovells seeks payment of \$255,214.00, representing 80% of Hogan Lovells' fees for services rendered plus 100% of expenses. As of the date of this Application, Hogan Lovells has received no payment for the fees and expenses requested herein.

5. Attached hereto as **Exhibit A** are the time records of Hogan Lovells Professionals, which provide a daily summary of the time spent by each Hogan Lovells Professional during the Fee Statement Period organized by matter, including a breakdown of disbursements incurred by Hogan Lovells during the Fee Statement Period.

6. Hogan Lovells charges \$.10 per page for photocopying.

7. Hogan Lovells charges \$1.00 per page for outgoing domestic facsimiles and does not charge for incoming facsimiles.

8. In accordance with Local Rule 2016-2, Hogan Lovells has reduced its request for compensation for non-working travel, if any, to 50% of its normal rate.

9. The undersigned has reviewed the requirements of Local Rule 2016-2 and certifies to the best of his information, knowledge, and belief that this Application complies with that Rule.

[Remainder of page intentionally left blank.]

WHEREFORE, Hogan Lovells respectfully requests that this Court: (a) allow Hogan Lovells (i) interim compensation in the amount of \$319,017.50 for actual, reasonable, and necessary professional services rendered on behalf of the Debtor during the period March 1, 2019 through and including March 31, 2019, and (ii) interim reimbursement in the amount of \$1,595.08 for actual, reasonable, and necessary expenses incurred during the same period; (b) authorize and direct the Debtor to pay to Hogan Lovells the amount of \$256,809.08 which is equal to the sum of 80% of Hogan Lovells' allowed interim compensation for the period (\$255,214.00) and 100% of Hogan Lovells' allowed expense reimbursement for the period (\$1,595.08); and (c) grant such other and further relief as is just and proper.

Dated: April 23, 2019  
New York, New York

Respectfully submitted,  
HOGAN LOVELLS US LLP

By: /s/ Christopher R. Donoho, III  
875 Third Avenue  
New York, New York 10022  
Telephone: 212-918-3000  
Facsimile: 212-918-3100  
Christopher R. Donoho, III, Esq. (*pro hac vice*)  
Christopher R. Bryant, Esq. (*pro hac vice*)  
John D. Beck, Esq. (*pro hac vice*)  
Email: chris.donoho@hoganlovells.com  
chris.bryant@hoganlovells.com  
john.beck@hoganlovells.com

*Co-Counsel to the Debtor and  
Debtor in Possession*

**IN THE UNITED STATES BANKRUPTCY COURT  
FOR THE DISTRICT OF DELAWARE**

*In re:*

OREXIGEN THERAPEUTICS, INC.,

Debtor.<sup>1</sup>

Chapter 11

Case No. 18-10518 (KG)

**Objection Deadline:**

**May 14, 2019 at 4:00 p.m. (ET)**

**NOTICE OF THIRTEENTH MONTHLY FEE STATEMENT OF HOGAN LOVELLS US  
LLP FOR PROFESSIONAL SERVICES AND DISBURSEMENTS AS CO-COUNSEL TO  
THE DEBTOR AND DEBTOR IN POSSESSION FOR THE PERIOD  
MARCH 1, 2019 THROUGH AND INCLUDING MARCH 31, 2019**

PLEASE TAKE NOTICE that today, Morris, Nichols, Arsht & Tunnell LLP as counsel to the Debtor in the above-captioned case, filed the attached **Thirteenth Monthly Fee Statement of Hogan Lovells US LLP for Professional Services and Disbursements as Co-Counsel to the Debtor and Debtor in Possession for the Period March 1, 2019 through and Including March 31, 2019** (the “Application”).

PLEASE TAKE FURTHER NOTICE that objections, if any, to the Application, must: (a) filed with the Clerk of the Bankruptcy Court, 824 North Market Street, 3<sup>rd</sup> Floor, Wilmington, Delaware 19801, by **May 14, 2019 at 4:00 p.m. (Eastern Time)** (the “Objection Deadline”); and (b) be served so as to be received on or before the Objection Deadline by:

i. the Debtor: Orexigen Therapeutics, Inc., 3344 North Torrey Pines Court, Suite 200, La Jolla, CA 92037;

ii. co-counsel to the Debtor: Hogan Lovells US LLP, 875 Third Avenue, New York, NY 10022, (Attn: Christopher R. Donoho, III, Esq.); and Morris, Nichols, Arsht & Tunnell LLP, 1201 N. Market Street, 16<sup>th</sup> Floor, Wilmington, DE 19801, (Attn: Robert J. Dehney, Esq.);

iii. counsel to the DIP Administrative Agent: Arnold & Porter Kaye Scholer LLP, 70 W. Madison St., Suite 4200, Chicago, IL 60602 (Attn: Tyler Nurnberg, Esq. and Alan Glantz, Esq.);

iv. counsel to certain of the DIP Lenders: Quinn Emanuel Urquhart & Sullivan, LLP, 865 S. Figueroa St., 10<sup>th</sup> Floor, Los Angeles, CA 90017 (Attn: Eric Winston, Esq. and Bennett Murphy, Esq.); and Whiteford Taylor Preston LLP, The Renaissance Center, Suite 500, 405 N. King Street, Wilmington, DE 19801 (Attn: Chris Samis, Esq. and L. Katherine Good, Esq.);

---

<sup>1</sup> The last four digits of the Debtor’s federal tax identification number are 8822. The Debtor’s mailing address for purposes of this Chapter 11 Case is 3344 North Torrey Pines Court, Suite 200, La Jolla, CA, 92037.

v. counsel to the Official Committee of Unsecured Creditors: Irell & Manella LLP, 840 Newport Center Drive, Suite 400, Newport Beach, CA 92660 (Attn: Jeffrey M. Reisner, Esq.); and

vi. the Office of the United States Trustee: J. Caleb Boggs Federal Building, Room 2207, 844 N. King Street, Wilmington, DE 19801, (Attn: Timothy J. Fox, Esq.).

A HEARING ON THE APPLICATION, IF NECESSARY, WILL BE HELD AT THE CONVENIENCE OF THE COURT AND NOTICE OF ANY SUCH HEARING WILL BE GIVEN ONLY TO THE OBJECTING PARTY OR PARTIES.

IF YOU FAIL TO RESPOND IN ACCORDANCE WITH THIS NOTICE, THE COURT MAY GRANT THE RELIEF REQUESTED BY THE APPLICATION WITHOUT FURTHER NOTICE OR HEARING.

April 23, 2019  
Wilmington, Delaware

**MORRIS, NICHOLS, ARSHT & TUNNELL LLP**

/s/ Tamara K. Mann

Robert J. Dehney (No. 3578)  
Andrew R. Remming (No. 5120)  
Tamara K. Mann (No. 5643)  
1201 N. Market St., 16th Floor  
P.O. Box 1347  
Wilmington, DE 19899-1347  
Telephone: (302) 658-9200  
Facsimile: (302) 658-3989  
rdehney@mnat.com  
aremming@mnat.com  
tmann@mnat.com

- and -

Christopher R. Donoho, III (admitted *pro hac vice*)  
Christopher R. Bryant (admitted *pro hac vice*)  
John D. Beck (admitted *pro hac vice*)

**HOGAN LOVELLS US LLP**

875 Third Avenue  
New York, NY 10022  
Telephone: (212) 918-3000  
Facsimile: (212) 918-3100  
chris.donoho@hoganlovells.com  
chris.bryant@hoganlovells.com  
john.beck@hoganlovells.com

*Counsel for Debtor and Debtor in Possession*

**Exhibit A**



Hogan Lovells US LLP  
 390 Madison Avenue  
 New York, NY 10017  
 T +1 212 918 3000  
 F +1 212 918 3100  
 www.hoganlovells.com

Orexigen Therapeutics, Inc.  
 Tom Lynch  
 General Counsel  
 3344 N. Torrey Pines Court. Suite 200  
 La Jolla, CA 92037

Date April 22, 2019  
 Invoice No 20600019305  
 Our ref 045803.000019  
 Partner Christopher R. Donoho  
 Email chris.donoho@hoganlovells.com  
 Fed ID 53-0084704

## Chapter 11

Summary	Amount
	USD
Professional Services	323,344.50
Less Non-Working Travel	(4,327.00)
Total Professional Services	319,017.50
 Total Disbursements and Charges	 1,595.08
Subtotal	320,612.58
<b>Total Due</b>	<b>320,612.58</b>

## Payment Details

Electronic payments should be sent to  
 Wells Fargo Bank NA, 420 Montgomery Street  
 San Francisco, CA 94104  
 Account: Hogan Lovells US LLP – Operating Account  
 SWIFT code: WFBUS6S Account No: 2000010688096  
 ABA #121000248 For Wire Transfers Only  
 ABA #054001220 (For ACH Transfers Only)

### Check Payment Instructions

Regular Mail:  
 Hogan Lovells US LLP  
 P.O. Box 75890  
 Baltimore, MD 21275-5890

Overnight Mail Only:  
 Lockbox Services 75890  
 Wells Fargo Bank  
 7175 Columbia Gateway Drive  
 ATTN: Hogan Lovells US LLP  
 Columbia, MD 21045

Payment requested  
 within 30 days from  
 invoice date

- 2 -

Date	April 22, 2019
Invoice No	20600019305
Our Ref	045803.000019

**Period** March 31, 2019

Detail by jurisdiction	Professional Services	Disbursements & Charges	Total USD
Hogan Lovells US LLP	319,017.50	1,595.08	320,612.58
Total	319,017.50	1,595.08	320,612.58

Disbursements & charges	Charges USD
Travel	367.34
Hospitality	40.05
Taxi	29.65
Search Fees	957.29
Document Production	168.75
EPIQ Other Case Specified Data Services	32.00
Total	1,595.08



- 3 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**Professional Services****03 - Hearings**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/25/19	Christopher R. Bryant	HLUS	935.00	0.90	841.50	Call with E. Einhorn regarding hearing (.1); prepare for disclosure statement hearing (.8)
03/25/19	John D Beck	HLUS	895.00	0.20	179.00	Review draft of hearing agenda (.1); discuss disclosure statement hearing division of responsibilities with E. Einhorn (.1)
03/26/19	Eric L Einhorn	HLUS	590.00	8.40	4,956.00	Outline and prepare for disclosure hearing (1.5); call with local counsel, C. Bryant and J. Beck regarding the SEC (.3); research note register procedures and solicitation procedures under the plan (1.4); call with J. Beck regarding the disclosure hearing (.1); prepare for disclosure hearing (1.6) email correspondence with J. Beck regarding hearing (.1); review J. Beck's comments to hearing outline (.5); further prepare for disclosure hearing (2.9)
03/27/19	Christopher R. Bryant	HLUS	935.00	1.30	1,215.51	Participate in hearing and numerous discussions with various constituencies prior to and after hearing (1.3)
03/27/19	John D Beck	HLUS	895.00	9.20	8,234.00	Further review materials in advance of disclosure statement hearing and practice presentation to court (2.5); meet at Morris Nichols offices to prepare for the disclosure statement hearing (3.5); attend disclosure statement hearing (2.0); meet back at Morris

- 4 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**03 - Hearings**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						Nichols to discuss next steps and related follow up (1.2)
03/27/19	Eric L Einhorn	HLUS	590.00	6.70	3,953.00	Prepare for hearing (1.8); conference with Lowenstein regarding shareholders' litigation (.2); conference with C. Bryant, J. Beck, committee counsel and counsel to lenders regarding SEC issues and shareholders' issues (1.1); strategize with local counsel and discuss hearing (1.7); attend hearing and present on procedures (1.9)
03/27/19	Sean A Feener	HLUS	590.00	3.20	1,888.00	Attend joint procedures hearing (2.0); related preparation and follow-up (1.2)
				<b>Subtotal</b>	<b>29.90</b>	<b>21,267.01</b>

**04 - DIP or Exit Financing**

Date	Name	LLP	Rate	Hours	Amount	Narrative
03/05/19	Christopher R. Bryant	HLUS	935.00	0.50	467.50	Review final cash collateral stipulation and correspondence with S. Feener regarding same (.5)
03/12/19	Christopher R. Bryant	HLUS	935.00	0.20	187.00	Review Quinn invoices and transmit to T. Lynch and Ernst & Young (.2)
03/13/19	Christopher R. Bryant	HLUS	935.00	0.40	374.00	Review updated cash reporting (.4)
				<b>Subtotal</b>	<b>1.10</b>	<b>1,028.50</b>

**05 - Litigation:Contested Matters, Adv. Proceedings, other Litigation**

Date	Name	LLP	Rate	Hours	Amount	Narrative
03/01/19	Pieter Van Tol	HLUS	1,195.00	0.60	717.00	Telephone conference with Cooley regarding status and next steps with respect to litigation (.6)

- 5 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**05 - Litigation:Contested Matters, Adv. Proceedings, other Litigation**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/06/19	Christopher R. Bryant	HLUS	935.00	0.20	187.00	Coordinate call with Cooley regarding litigation and insurance matters (.2)
03/07/19	Christopher R. Bryant	HLUS	935.00	0.50	467.50	Review Cooley call summaries and follow up with J Reisner regarding same (.3); coordinate call with Irell and Cooley regarding insurance matters (.2)
03/11/19	Christopher R. Bryant	HLUS	935.00	0.60	561.00	Call with Cooley, Irell team and Hogan Lovells team regarding insurance matters regarding 9th circuit case and related follow-up (.6)
03/12/19	Christopher R. Bryant	HLUS	935.00	0.70	654.50	Correspondence with J. Beck, E. Einhorn and S. Feener regarding stay matter (.3); review stay article and research regarding same and transmit to J. Reisner and K. Lynch (.4)
03/12/19	Christopher R. Bryant	HLUS	935.00	0.30	280.50	Correspondence with K. Lyman and E. Einhorn regarding 9th Circuit litigation matters (.2); correspondence with E. Einhorn regarding 9th circuit litigation (.1)
03/13/19	Christopher R. Bryant	HLUS	935.00	0.50	467.50	Review 9th Circuit litigation amended complaint and proof of claim and correspondence with K. Lyman regarding same (.5)
03/13/19	Eric L Einhorn	HLUS	590.00	0.20	118.00	Diligence related to securities litigation (.2)
03/15/19	Christopher R. Bryant	HLUS	935.00	0.10	93.50	Transmit plan and Disclosure Statement to J. Lombard in connection with litigation matters (.1)
03/15/19	Eric L Einhorn	HLUS	590.00	2.00	1,180.00	Search for precedent of adversary complaint in

- 6 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**05 - Litigation:Contested Matters, Adv. Proceedings, other Litigation**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						Delaware (.8); email correspondence with J. Lee regarding adversary complaint (.1); draft adversary complaint (1.1)
03/16/19	Eric L Einhorn	HLUS	590.00	2.60	1,534.00	Review and revise adversary complaint (2.4); conference with C. Bryant regarding adversary complaint (.2)
03/17/19	Eric L Einhorn	HLUS	590.00	1.00	590.00	Review and revise adversary complaint (1.0)
03/18/19	Christopher R. Bryant	HLUS	935.00	0.90	841.50	Call with J. Reisner regarding Cooley stipulation and open items and related follow-up (.3); revise Cooley stipulation and transmit to J. Reisner for review (.4); transmit revised stipulation to Cooley with cover note (.2)
03/18/19	Christopher R. Bryant	HLUS	935.00	0.30	280.50	Conference with E. Einhorn regarding adversary complaint (.3)
03/18/19	Eric L Einhorn	HLUS	590.00	3.10	1,829.00	Revise adversary complaint (1.0); further review and revise adversary complaint (2.1)
03/19/19	Christopher R. Bryant	HLUS	935.00	0.50	467.50	Review correspondence from J. Lombard regarding stipulation and reply to same and coordinate call with Irell (.5)
03/19/19	John D Beck	HLUS	895.00	0.20	179.00	Discuss drafting of adversary complaint for subordination and objection to claim with E. Einhorn (.2)
03/19/19	Eric L Einhorn	HLUS	590.00	3.20	1,888.00	Conference with J. Beck regarding adversary complaint (.2); review and revise adversary complaint (.9); research related to subordination (1.2); further review and revise

- 7 -

Orexigen Therapeutics, Inc.	Date	April 22, 2019
	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**05 - Litigation:Contested Matters, Adv. Proceedings, other Litigation**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						adversary complaint (.9)
03/20/19	Christopher R. Bryant	HLUS	935.00	1.30	1,215.50	Call with J. Lombard, M. Kelley and J. Reisner regarding AIG/Cooley stipulation and revise and circulate stipulation to Cooley (.9); transmit revised stipulation to J. Reisner for review (.1); correspondence with Cooley regarding plaintiffs' limited objection (.3)
03/20/19	John D Beck	HLUS	895.00	1.30	1,163.50	Review draft adversary complaint seeking to subordinate and objecting to claims of class plaintiffs (1.2); discuss same with E. Einhorn (.1)
03/20/19	Eric L Einhorn	HLUS	590.00	3.90	2,301.00	Review and revise adversary complaint (1.9); review shareholder objection (.3); further review and revise adversary complaint (1.7)
03/21/19	Christopher R. Bryant	HLUS	935.00	0.40	374.00	Revise Certificate of Counsel per J. Reisner comments and circulate for sign-off (.4)
03/23/19	Christopher R. Bryant	HLUS	935.00	0.10	93.50	Follow-up with Irell regarding status of Certificate of Counsel for Cooley (.1)
03/25/19	Christopher R. Bryant	HLUS	935.00	0.50	467.50	Transmit revised Cooley/AIG stipulation to B. Murphy with cover note and finalize certificate of counsel and coordiante filing (.5)
03/26/19	Eric L Einhorn	HLUS	590.00	0.40	236.00	Call with C. Bryant and A. Behlmann regarding 9th circuit litigation (.4)
03/28/19	Christopher R. Bryant	HLUS	935.00	0.50	467.50	Correspondence with J. Lombard regarding Certificate of Counsel and

- 8 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**05 - Litigation:Contested Matters, Adv. Proceedings, other Litigation**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						draft of insert for order (.5)
03/29/19	Christopher R. Bryant	HLUS	935.00	1.20	1,122.00	Revise COC per Lowenstein comments and circulate same for review (.4); correspondence with J. Reisner regarding COC (.1); call with J. Reisner regarding plaintiffs' claim and insurance matters (.3); coordinate filing of COC and correspondence with T. Mann regarding same (.4)
				<b>Subtotal</b>	<b>27.10</b>	<b>19,776.50</b>

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
03/01/19	Scott Friedman	HLUS	1,175.00	2.50	2,937.50	Review of applicable law to disclosure and tax aspects of reorganization (2.5)
03/01/19	Christopher R. Bryant	HLUS	935.00	3.80	3,553.00	Draft and revise plan per committee and other comments and transmit for review with cover notes (.9); review revisions to motion and provide comments to same (1.8); correspondence with S Feener regarding budget and plan open items (.4); review and revise note register provisions and correspondence with S Feener regarding same (.7)
03/01/19	Christopher R. Bryant	HLUS	935.00	0.60	561.00	Call with Cooley and HL teams regarding litigation and plan issues (.6)
03/01/19	John D Beck	HLUS	895.00	0.70	626.50	Review additional revisions to plan and disclosure statement circulated by the Committee and other revisions addressing treatment of certain claims

- 9 -

Orexigen Therapeutics, Inc.	Date	April 22, 2019
	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						(.3); review and revise draft note register procedures (.4)
03/01/19	Sean A Feener	HLUS	590.00	0.60	354.00	Call regarding plan tax questions (.2); necessary edits to plan and DS (.4)
03/02/19	Christopher R. Bryant	HLUS	935.00	1.40	1,309.00	Attention to notice to noteholders and note register issues and correspondence with KCC regarding same (1.4)
03/02/19	Sean A Feener	HLUS	590.00	1.00	590.00	Review and revise note register procedures and send to parties in interest (1.0)
03/03/19	Christopher R. Bryant	HLUS	935.00	1.00	935.00	Correspondence with J. Reisner regarding plan status (.1); correspondence with S. Feener regarding plan, DS and motion and filing prep (.5); correspondence with S. Friedman regarding trust vs. LLC matter (.4)
03/03/19	John D Beck	HLUS	895.00	0.40	358.00	Review comments to note register procedures from Quinn Emmanuel (.2); email correspondence with C. Bryant and S. Feener regarding open issues in the plan and disclosure statement (.2)
03/03/19	Sean A Feener	HLUS	590.00	1.00	590.00	Review Plan, Disclosure Statement and joint procedures motion (1.0)
03/04/19	Christopher R. Donoho	HLUS	1,375.00	2.80	3,850.00	Review revised plan and consider open issues (1.6); correspondence with C. Bryant regarding joint plan concept and issues surrounding treatment of classes (.6); correspondence with creditors regarding plan terms (.6)

- 10 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/04/19	Scott Friedman	HLUS	1,175.00	2.00	2,350.00	Conference call (.3); review and analyze disclosure plan in light of proposed structure of wind down entity and disclosure (.7); review and analyze applicable law regarding characterization of wind down entity as a pass through (.6); all hands conference call with Quinn Emmanuel (.4)
03/04/19	Christopher R. Bryant	HLUS	935.00	0.30	280.50	Initial review of escrow agreement (.3)
03/04/19	Christopher R. Bryant	HLUS	935.00	5.00	4,675.00	Call with S. Friedman, C. Chen, J. Beck and others regarding wind-down mechanics (.2); emails with C. Donoho regarding plan distribution and related matters (.5); emails with J. Reisner regarding plan open matters (.4); calls with S. Feener regarding open items on plan, Disclosure Statement and motion (.4); numerous emails regarding open issues in plan, Disclosure Statement and motion with S. Feener, J. Beck, J. Reisner, et al. (.9); review B. Feder edits to documents (.4); correspondence with B. Murphy regarding wind-down entity and conference call with B. Murphy and HL team regarding same (.4); call with S. Feener regarding plan and Disclosure Statement edits (.2); review edits to plan and Disclosure Statement and provide input (1.6)
03/04/19	John D Beck	HLUS	895.00	1.10	984.50	Call with tax team regarding tax issues



- 11 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						regarding the plan (.2); email correspondence with S. Feener regarding certain comments from Committee to the plan (.1); review revised drafts of plan and disclosure statement (.7); review comments to plan from B. Feder (.1)
03/04/19	Catherine Chen	HLUS	730.00	1.50	1,095.00	Conference to discuss disclosure statement (0.3); conference to discuss wind up entity structure (0.4); research treatment of wind up entity (0.3); prepare comments to disclosure statement (0.5)
03/04/19	Eric L Einhorn	HLUS	590.00	3.30	1,947.00	Email correspondence with C. Bryant and J. Beck regarding tax issues (.1); review email correspondence from S. Friedman regarding tax issues (.2); attention to changes in the joint procedures motion (.5); review lenders' comments to note register (.6); revise chapter 11 plan per committee's comments (.2); attention to chapter 11 plan (1.0); call with S. Friedman, C. Bryant, J. Beck, and S. Feener regarding tax issues (.2); attention to wind down work stream (.2); review United States Bank's comments to joint procedures motion (.3)
03/04/19	Sean A Feener	HLUS	590.00	7.20	4,248.00	Review and revise Plan, Ballots, Disclosure Statement and Joint Procedures Motion/Order (4.2); calls with C. Bryant, B. Murphy, J. Beck and tax team regarding wind down

- 12 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						entity and plan/Disclosure Statement tax issues (.8); further revisions to documents based on comments from parties in interest (2.2)
03/05/19	Scott Friedman	HLUS	1,175.00	2.90	3,407.50	Determine applicable law for proposed Delaware statutory trust to use for Wind Down entity (.9); review, edit and analyze disclosure and plan of reorganization (2.0)
03/05/19	Christopher R. Bryant	HLUS	935.00	9.20	8,602.00	Calls with S. Feener regarding plan edits and proposed distributions (.4); review J. Reisner edits and correspondence with J. Reisner and B Murphy regarding same (.4); review revisions to plan and Disclosure Statement and tax comments and correspondence with S. Feener regarding same (.7); correspondence with C. Chen regarding liquidating trust (.2); conferences with C. Chen and S. Friedman regarding trust matters (.3); correspondence with S. Feener regarding circulating revise drafts to all (.2); consideration of remaining open issues and service related matters and correspondence with S. Feener, MNAT and KCC regarding same (.8); numerous emails regarding plan and Disclosure Statement open issues with J. Reisner, B. Murphy, S. Friedman etc. (.9); conferences and calls with J. Beck, E. Einhorn and S. Feener regarding plan, Disclosure Statement

- 13 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						and order and motion (.8); revised documents and provide input (3.1); review tax edits to Disclosure Statement and correspondence with S. Friedman regarding same (.6); conference with S. Feener regarding open items for filing, etc. (.4); correspondence with T. lynch regarding 401(k) figures for Disclosure Statement (.2); correspondence with J. Reisner regarding open plan issues (.2)
03/05/19	John D Beck	HLUS	895.00	2.30	2,058.50	Discuss open items of the plan and overall status of case with C. Bryant (.5); discuss review of claims report and general status of open items with C. Bryant, S. Feener and E. Einhorn (.2); further review ballots and notices (1.2); Review changes to disclosure statement from tax team (.2); discuss same with S. Feener (.1); discuss certain plan provisions with E. Einhorn (.1)
03/05/19	Catherine Chen	HLUS	730.00	2.60	1,898.00	Review/analyze structuring of wind-down entity and prepare corresponding changes to plan and disclosure schedule (2.6)
03/05/19	Eric L Einhorn	HLUS	590.00	0.20	118.00	Conference with C. Bryant, J. Beck and S. Feener regarding claims register (.2);
03/05/19	Sean A Feener	HLUS	590.00	6.10	3,599.00	Continued revisions to plan, disclosure statement, ballots and joint procedures motion (3.2); numerous calls and emails

- 14 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						related to same (1.2); final revisions and send redlines to parties in interest for comment (1.7)
03/06/19	Christopher R. Donoho	HLUS	1,375.00	3.00	4,125.00	Review of final drafts of plan (1.4); correspondence internally and with creditors related to final issues and filing considerations (1.3); office conference with C. Bryant regarding plan filing considerations (.3)
03/06/19	Christopher R. Bryant	HLUS	935.00	10.40	9,724.00	Correspondence with D. Demko regarding distribution estimates and plan and review distribution schedule (.5); conference call with Ernst & Young and Hogan Lovells teams regarding plan and distribution matters (.5); further review of plan, Disclosure Statement and motion and provide comments correspondence with S. Feener regarding edits and open items (.5); conference with S. Feener regarding open items in documents and correspondence regarding same (.4); attention to attachments to filings (.3); call with S. Feener regarding signatures and documents (.1); correspondence with B. Murphy and Ernst & Young regarding projected distributions (.4); follow-up with J. Reisner regarding Committee status (.1); review revised ballots and provide comments (.9); attention to draft of wind down entity agreement and escrow agreement (.4);

- 15 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						review updated projected distribution schedule and call with B. Murphy, Ernst & Young and Hogan Lovells teams (.4); attention to Nalpropion holdback amounts for disclosures statement and distribution purposes (.2); conference with S. Feener regarding filing preparation and open issues (.2); review D/S for references to certain pending matters (.4); revise Disclosure Statement regarding Nalpropion holdbacks (.4); correspondence regarding co-sponsorship plan by Committee and consider potential edits to plan and related filings (.4); calls with MNAT regarding filing and objection deadline (.2); review of revised documents for filing and correspondence with T. Lynch, B. Murphy and others regarding filing and open points (2.9); review updated estimated recovery schedule (.3); correspondence with K. Lyman and J. Reisner regarding sign off, plan co-sponsorship, etc. (.4); numerous emails with MNAT regarding dates, filings, open points, etc. and coordinate service with S. Feener and KCC (.5)
03/06/19	John D Beck	HLUS	895.00	3.50	3,132.50	Review additional revisions to plan, disclosure statement and joint procedures motion (.8); call with Ernst & Young regarding reserve

- 16 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						estimates and estimated distributions (.5); email correspondence with B. Murphy and Ernst & Young regarding professional fee reserve and distribution estimates (.1); review final versions of plan, disclosure statement, ballots and procedures motion prior to filing (2.1)
03/06/19	Sean A Feener	HLUS	590.00	6.20	3,658.00	Various calls and emails regarding plan and disclosure statement (1.5); process edits to same and continue to draft and revise (2.6); emails and calls with MNAT regarding filing (.8); finalize documents for filing (1.3)
03/07/19	Christopher R. Bryant	HLUS	935.00	1.40	1,309.00	Correspondence with S. Feener, MNAT and KCC regarding service list (.5); correspondence with J. Reisner regarding escrow (.1); correspondence with J. Beck and B. Murphy regarding McKesson stip and review stip and APA and consider issues (.8)
03/07/19	John D Beck	HLUS	895.00	2.50	2,237.50	Review three McKesson stipulations, APA, and Plan regarding informal objection to plan from McKesson (2.0); draft summary of provisions related to same (.5)
03/08/19	Christopher R. Donoho	HLUS	1,375.00	0.80	1,100.00	Correspondence regarding plan with creditors and voting discussion (.8)
03/08/19	Christopher R. Bryant	HLUS	935.00	0.20	187.00	Call with J Beck regarding McKesson (.2)
03/08/19	John D Beck	HLUS	895.00	0.40	358.00	Call with R. Cobb, Kerri Mumford and C. Bryant regarding McKesson

- 17 -

Orexigen Therapeutics, Inc.	Date	April 22, 2019
	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						treatment in plan (.2); discuss same with C. Bryant (.2)
03/09/19	Christopher R. Bryant	HLUS	935.00	0.80	748.00	Correspondence with Ernst & Young regarding edits to plan and Disclosure Statement and transmit revised versions to B Murphy (.6); correspondence with B Murphy regarding same (.2)
03/11/19	Christopher R. Bryant	HLUS	935.00	1.10	1,028.50	Call with E. Einhorn regarding claim subordination issue (.2); review E. Einhorn claim subordination analysis and transmit to Irell (.9)
03/11/19	Christopher R. Bryant	HLUS	935.00	0.10	93.50	Follow-up with B. Murphy regarding Plan and Disclosure Statement (.1)
03/11/19	Christopher R. Bryant	HLUS	935.00	0.90	841.50	Review and mark-up U.S. Bank escrow agreement (.7); correspondence with K. Lyman regarding subordination issues (.2)
03/11/19	Eric L Einhorn	HLUS	590.00	1.20	708.00	Research related to subordination (.8); summarize research on subordination issue (.4)
03/12/19	Christopher R. Bryant	HLUS	935.00	1.30	1,215.50	Review B. Murphy's edits to plan and Disclosure Statement and correspondence with B. Murphy regarding same (.4); revise plan and disclosure statement and transmit to debtor team with explanatory note (.9)
03/12/19	John D Beck	HLUS	895.00	0.30	268.50	Review revised plan and disclosure statement addressing McKesson reserve (.3)
03/13/19	Christopher R. Bryant	HLUS	935.00	5.90	5,516.50	Draft and revise escrow agreement and transmit

- 18 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						with cover note to T. Lynch, Ernst & Young and Hogan Lovells team for review (2.9); correspondence with B. Pickering and D. Demko regarding plan edits (.2); correspondence with Demko regarding wind down waterfall (.2); correspondence with B. Murphy and D. Demko regarding plan edits and estimated recoveries (.4); call with B. Pickering and D. Demko regarding estimated recovery amounts and plan (.2); revise Disclosure Statement and circulate for review to B. Murphy and Hogan Lovells team (.4); correspondence with J. Beck regarding disputed claims text in plan and objection process (.5); correspondence with T. Lynch regarding edits to plan and Disclosure Statement (.1); transmit revised plan and Disclosure Statement statement to R. Cobb for onward distribution (.2); draft of note register notice (.8)
03/14/19	Christopher R. Donoho	HLUS	1,375.00	0.60	825.00	Update on timing and plan progress (.6)
03/14/19	Christopher R. Bryant	HLUS	935.00	4.70	4,394.50	Draft of note register notice (1.9); follow-up with T. Lynch regarding 401(k) payments (.1); call with T. Lynch and D. Demko regarding plan matters (.5); initial prep of plan supplement (.8) review of draft trust agreement and revise (1.4)



- 19 -

Orexigen Therapeutics, Inc.

Date April 22, 2019

Invoice No 20600019305

Our Ref 045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/15/19	Christopher R. Bryant	HLUS	935.00	5.10	4,768.50	Prepare for call with Hogan Lovells team regarding plan and claim objections for voting purposes (.5); call with Hogan Lovells team regarding plan and claim objections (1.4); correspondence with S. Feener regarding objections to claims (.1); revise escrow agreement and transmit to B. Murphy and J. Reisner with cover note (.4); attention to estimation motion and consider estimation issues (.6); draft of note register notice and plan supplement (1.5); transmit proposed McKesson revisions in plan and Disclosure Statement to Irell with cover note (.3); transmit Takeda data to Irell and BRG with cover note (.3)
03/15/19	John D Beck	HLUS	895.00	4.20	3,759.00	Reviewing plan, disclosure statement and interim procedures order and begin drafting hearing outline for presentation to the court at disclosure statement hearing (4.2)
03/15/19	Jennifer Lee	HLUS	530.00	1.70	901.00	Correspondence with J. Beck and E. Einhorn (.2); research regarding adversary complaints involving subordination of claims in Delaware (1.0); research regarding approval of disclosure statements in chapter 11 cases in Delaware (.5)
03/15/19	Sean A Feener	HLUS	590.00	3.60	2,124.00	Call with J. Beck, C. Bryant and E. Einhorn related to outstanding plan/Disclosure

- 20 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						Stateement issues and joint procedures hearing (1.4); emails with MNAT regarding precedent documents (.4); draft sample response to disclosure statement objections (1.8)
03/16/19	Christopher R. Bryant	HLUS	935.00	0.90	841.50	Consideration of objections to plaintiffs' claim and estimation matters and related research (.7); related emails (.2)
03/17/19	Christopher R. Bryant	HLUS	935.00	0.50	467.50	Emails with J. Beck and E. Einhorn regarding plan and Disclosure Statement and next steps (.5)
03/17/19	John D Beck	HLUS	895.00	3.40	3,043.00	Continue reviewing disclosure statement precedent related to liquidating plans and requirements for approval of disclosure statement (1.2); continue drafting outline for presentation to court at confirmation hearing (2.2)
03/18/19	Christopher R. Bryant	HLUS	935.00	0.90	841.50	Call with Ernst & Young and Hogan Lovells teams regarding plan confirmation matters (.3); correspondence regarding claims register from S. Feener (.4); call with D. Demko and B. Pickering regarding claims and voting matters (.2)
03/18/19	Christopher R. Bryant	HLUS	935.00	3.40	3,179.00	Correspondence with R. Cobb regarding McKesson (.2); draft and revise notices and exhibits (2.1); review claims charts and consider voting matter (1.1)
03/18/19	John D Beck	HLUS	895.00	0.40	358.00	Discuss plan voting with Ernst & Young and Hogan

- 21 -

Orexigen Therapeutics, Inc.	Date	April 22, 2019
	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						teams and related follow up (.4)
03/18/19	John D Beck	HLUS	895.00	1.20	1,074.00	Continue reviewing materials in preparation for disclosure statement and joint procedures hearing (1.2)
03/18/19	Eric L Einhorn	HLUS	590.00	0.50	295.00	Attention to wind down work stream (.2); follow up call with Ernst Young, C. Bryant, J. Beck and S. Feener regarding voting power of creditors (.3);
03/19/19	Christopher R. Bryant	HLUS	935.00	4.90	4,581.50	Correspondence with Irell regarding McKesson edits to plan and Disclosure Statement (.2); review correspondence from MNAT and S. Feener regarding service of plan and Disclosure Statement on certain Third parties and reply (.4); review of B. Murphy draft of wind down entity agreement and draft and revise same (3.7); review McKesson edits to Disclosure Statement and correspondence with R. Cobb and B. Murphy regarding same (.4); transmit draft note register notice to B. Murphy and B. Feder for review (.2)
03/19/19	John D Beck	HLUS	895.00	0.20	179.00	Review and consider McKesson comments to disclosure statement (.2)
03/19/19	Sean A Feener	HLUS	590.00	1.10	649.00	Confer with C. Bryant regarding note register notices (.3); review and revise same (.8)
03/20/19	Christopher R. Bryant	HLUS	935.00	4.40	4,114.00	Correspondence with B. Murphy and J. Beck regarding McKesson edits to Disclosure Statement (.2); call with B. Murphy

- 22 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						regarding McKesson edits and correspondence with R. Cobb regarding same (.4); correspondence with Hogan Lovells team regarding potential objections and strategy (.4); review limited objection from securities plaintiff to Disclosure Statement and plan and correspondence with B. Murphy, J. Reisner and Hogan Lovells team regarding same (.9); provide update to T. Lynch and Ernst & Young regarding limited objection and proposed resolutions (.4); revising of plan per plaintiffs objection (1.0); review Wilmington objections to Disclosure Statement and plan and correspondence regarding same (.5); emails with J. Reisner and others regarding treatment of securities plaintiff claims and consideration of issues (.4); correspondence with B. Murphy regarding plan strategy (.2)
03/20/19	John D Beck	HLUS	895.00	0.80	716.00	Review class action plaintiffs' objection to disclosure statement (.4); email correspondence with Hogan regarding same (.2); review Wilmington Trust reservations of right to the disclosure statement and email correspondence regarding same (.2)
03/21/19	Christopher R. Bryant	HLUS	935.00	0.70	654.50	Call with B. Murphy regarding plan (.1); call with A. Remming regarding plan (.4); call with E. Einhorn regarding plan (.2)

- 23 -

Orexigen Therapeutics, Inc.

Date April 22, 2019

Invoice No 20600019305

Our Ref 045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/21/19	John D Beck	HLUS	895.00	2.20	1,969.00	Continue reviewing procedures motion, disclosure statement and plan in preparation for disclosure statement hearing (2.2)
03/22/19	Christopher R. Bryant	HLUS	935.00	1.60	1,496.00	Call with Lowenstein and MNAT regarding plan and Disclosure Statement revisions and related follow-up (.5); review edits to escrow agreement draft and correspondence with R. Izakelian regarding same (.3); revising of plan (.8)
03/23/19	Christopher R. Bryant	HLUS	935.00	6.00	5,610.00	Correspondence with J. Lombard regarding revisions to plan and Disclosure Statement and treatment of litigation information, and coordinate call with T. Lynch and Hogan Lovells team (.3); revise escrow and transmit to US Bank with cover note (.5); follow-up with Quinn and Kelley/Drye regarding note register notice (.1); revise plan and Disclosure Statement and transmit to all with cover notes (5.1)
03/24/19	Christopher R. Bryant	HLUS	935.00	0.70	654.50	Correspondence with B. Murphy regarding document presentation plan and Disclosure Statement edits, etc. (.4); review note register notice comments form B. Murphy and correspondence with B. Murphy regarding same (.3)
03/24/19	Eric L Einhorn	HLUS	590.00	0.70	413.00	Prepare for disclosure statement hearing (.7)
03/25/19	Christopher R. Donoho	HLUS	1,375.00	3.10	4,262.50	Correspondence regarding key terms of plan including

- 24 -

Orexigen Therapeutics, Inc.	Date	April 22, 2019
	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						treatment of subordinated creditors (.7); review of key plan terms in advance of disclosure statement hearing (1.8); correspondence with creditors regarding same (.6)
03/25/19	Scott Friedman	HLUS	1,175.00	0.80	940.00	Planning regarding disclosure and request to debtors for tax status (.4); planning regarding finalization of disclosure and hearing (.2); confer with C. Bryant and emails from co-counsel (.2)
03/25/19	Christopher R. Bryant	HLUS	935.00	0.20	187.00	Review B. Feder comments to note register notice and respond (.2)
03/25/19	John D Beck	HLUS	895.00	5.60	5,012.00	Continue preparing for disclosure statement hearing and revising outline of presentation to court (4.2); review Ernst & Young's analysis of voting on the plan and related analysis of underlying claims (1.4)
03/25/19	Eric L Einhorn	HLUS	590.00	6.40	3,776.00	Prepare for disclosure statement hearing (2.2); outline note register and ballot solicitation procedures (2.3); further prepare for disclosure statement hearing (1.9)
03/26/19	Christopher R. Bryant	HLUS	935.00	13.40	12,529.00	Further prep of note register notices for individual noteholders (2.4); preliminary review of SEC letter regarding plan and disclosure statement and correspondence with MNAT regarding same (.6); call with Lowenstein regarding plan and disclosure statement (.4);

- 25 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						correspondence with B. Murphy and J. Reisner regarding Lowenstein edits to plan and disclosure statement (.4); correspondence with J. Lombard regarding retention of documents (.2); various emails with Cooley and B. Murphy regarding document retention matters (.5); conference call with MNAT and HL teams regarding SEC letter and related follow-up (.4); call with J. Reisner regarding edits to plan and disclosure statement (.3); call with B. Murphy regarding plan and disclosure statement and strategy (.2); review Lowenstein edits, revise plan and disclosure statement and circulate for review (2.0); review draft email to SEC and provide comments and transmit final to all (.4); call with Lowenstein regarding certificate of counsel (.2); revise plan and disclosure statement and circulate to all (1.9); hearing prep with J. Beck and E. Einhorn (.7); call with J. Beck regarding hearing and strategy (.4); review SEC's email and email to MNAT and HL teams regarding same (.3); correspondence with T. Lynch regarding document matters (.1); correspondence with B. Pickering regarding hearing (.1); review revised order and correspondence with S. Feener regarding same (.5); correspondence regarding SEC letter (.2);

- 26 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						review J. Reisner comments and reply (.3); further revise plan and disclosure statement and circulated to Lowenstein with cover note (.5); correspondence with SEC regarding comments to Plan and disclosure statement (.4)
03/26/19	Christopher R. Bryant	HLUS	935.00	0.30	280.50	Correspondence regarding Quinn and US Bank invoices (.3)
03/26/19	John D Beck	HLUS	895.00	6.80	6,086.00	Review SEC objection to plan and disclosure statement (.1); Discuss SEC Objection with MNAT, C. Bryant and E. Einhorn (.2); review Indianapolis Downs case and cases cited in SEC letter in preparation for potential objection (1.5); discuss hearing with E. Einhorn (.1); review and provide comment to E. Einhorn's outline on hearing presentation on voting, tabulation and solicitation procedures (.5); continue revising hearing outline and review materials related to same (4.2); discuss same with C. Bryant (.2)
03/26/19	Sean A Feener	HLUS	590.00	1.10	649.00	Review proposed joint procedures order against recent updates to plan and Disclosure Statement (1.1)
03/26/19	Sean A Feener	HLUS	590.00	1.80	1,062.00	Review latest drafts of Plan and Disclosure Statement (.8); emails regarding same (.4); hearing preparation (.6)
03/27/19	Christopher R. Bryant	HLUS	935.00	7.10	6,638.49	Working travel from home to Delaware including prepping for hearing (2.4); conferences, calls and



- 27 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						emails with Hogan Lovells team, Andrew Remming, B. Murphy, J. Reisner, M. Lowenstein regarding hearing and open points in plan and disclosure statement and review revisions (2.6); correspondence with T. Lynch and B. Pickering regarding hearing (.3); attention to note register list (.4); working travel from DE to NYC (1.4);
03/27/19	Sean A Feener	HLUS	590.00	1.80	1,062.00	Review and revise Disclosure Statement and Plan (1.1); conference with Hogan Lovells team and parties in interest regarding same (.7)
03/28/19	Christopher R. Bryant	HLUS	935.00	12.00	11,220.00	Correspondence with B. Murphy regarding plan and disclosure statement and note register (.1); correspondence with J. Beck regarding SEC, plan and disclosure statement (.2); correspondence with J. Beck and Ernst & Young regarding funds for distribution (.2); call with J. Lee regarding note register notice packages (.2); correspondence with J. Reisner regarding plan (.1); preparation of exhibits to note register notice and finalize with J. Lee for transmittal (.8); correspondence with J. Lombard, B. Murphy and J. Reisner regarding document retention matters and consider same (.4); coordinate with S. Feener revised plan and disclosure statement (.2); revise plan and disclosure statement per court

- 28 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						hearing and final Lowenstein comments and transmit to all for final review with cover notes (2.8); attention to noteholder list for transmittals of note register notice (.2); further drafting and revising of noteholder register notices (6.4); call with M. Etkin regarding edits to disclosure statement and correspondence with group regarding same (.2); correspondence with T. Lynch regarding execution of revised plan and disclosure statement (.2)
03/28/19	John D Beck	HLUS	895.00	0.90	805.50	Review and analyze revisions to the plan and disclosure statement to accurately reflect the agreements on the record at the disclosure statement hearing (.9)
03/28/19	Sean A Feener	HLUS	590.00	0.40	236.00	Emails regarding solicitation versions of plan and DS (.4)
03/29/19	Christopher R. Bryant	HLUS	935.00	5.10	4,768.50	Review comments from J. Reisner to plan and D/S (.2); revise plan and D/S and circulate final versions to all parties and coordinate filing with MNAT (1.1); calls and emails with J. Lee regarding notices and coordinate mailing (1.1); correspondence with all parties regarding filing or revised plan and D/S and coordinate with MNAT (.9); correspondence with M Etkin regarding document retention (.1); call with J. Lee regarding note matters (.4);

- 29 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**07 - Plan and Disclosure Statement**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						correspondence with J. Reisner regarding escrow account set up and next steps (.2); correspondence with US Bank regarding escrow agreement and timing (.3); correspondence with R. Cobb and A. Remming regarding plan (.4); consider reserves and escrows to be established (.4)
03/29/19	Jennifer Lee	HLUS	530.00	4.70	2,491.00	Confer with C. Bryant regarding note register notices (.1); assist with preparation and delivery of note register notices for purposes of voting on the plan and distributions under the plan (4.6)
03/30/19	Christopher R. Bryant	HLUS	935.00	1.40	1,309.00	Attention to note register notices and transmit to B. Murphy (.5); attention to solicitation and case next steps (.9)
			<b>Subtotal</b>	<b>226.80</b>	<b>198,400.49</b>	

**08 - Claims Administration and Objections**

Date	Name	LLP	Rate	Hours	Amount	Narrative
03/01/19	John D Beck	HLUS	895.00	0.30	268.50	Review E. Einhorn analysis of potentially late filed claims and basis for objection (.3)
03/04/19	Eric L Einhorn	HLUS	590.00	1.30	767.00	Email correspondence with Ernst Young regarding claim objections (.1); conference with C. Bryant regarding claim objections (.2); research related to government entities (1.0)
03/05/19	Christopher R. Bryant	HLUS	935.00	1.00	935.00	Correspondence with M. Giugliano regarding adjournment of claim objection hearing (.2);

- 30 -

Orexigen Therapeutics, Inc.	Date	April 22, 2019
	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**o8 - Claims Administration and Objections**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						conference with E. Einhorn and J. Beck regarding potential claim objections and related emails (.8)
03/05/19	John D Beck	HLUS	895.00	0.20	179.00	Discuss review of claims report and general status of open items with C. Bryant, S. Feener and E. Einhorn (.2)
03/05/19	Eric L Einhorn	HLUS	590.00	3.50	2,065.00	Draft claim objections (2.1); email correspondence with Ernst Young regarding claim objections (.1); review and revise claim objections (.4); email correspondence with C. Bryant regarding claim objections (.2); conference with J. Beck regarding claim objections (.1); diligence related to claim objections (.4); conference with C. Bryant and J. Beck (.2)
03/06/19	Christopher R. Bryant	HLUS	935.00	0.50	467.50	Numerous emails regarding claim objections and hearing dates (.5)
03/06/19	John D Beck	HLUS	895.00	0.20	179.00	Discuss claim objections with E. Einhorn (.1); email correspondence with Morris Nichols regarding omnibus claim objections (.1)
03/06/19	Eric L Einhorn	HLUS	590.00	1.40	826.00	Attention to late filed claims (.1); email correspondence with local counsel regarding omnibus hearing (.1); email correspondence with Ernst Young regarding objection exhibits (.1); diligence related to claim objections (1.0); conference with C. Bryant regarding objection to claim objection (.1)
03/07/19	Eric L Einhorn	HLUS	590.00	4.30	2,537.00	Draft two claim objections

- 31 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**o8 - Claims Administration and Objections**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						(2.3); review and revise claim objections (2.0)
03/08/19	Christopher R. Bryant	HLUS	935.00	3.00	2,805.00	Call with B. Murphy regarding McKesson (.3); call with R. Cobb, K. Mumford and J. Beck regarding plan and Disclosure Statement (.3); call with B. Murphy regarding plan and Disclosure Statement edits and correspondence with R. Cobb regarding same (.4); revise plan and Disclosure Statement and transmit to Ernst & Young for review (1.3); call with B. Pickering regarding plan and McKesson (.3); review updated projected recoveries (.4)
03/08/19	Eric L Einhorn	HLUS	590.00	3.40	2,006.00	Call with C. Bryant regarding claim objections and chapter 11 plan (.3); review and revise claim objections (1.6); email correspondence with Ernst Young regarding claim objections (.1); further review and revise claim objections (1.4)
03/10/19	Christopher R. Bryant	HLUS	935.00	0.40	374.00	Correspondence with E. Einhorn and D. Demko regarding objections
03/10/19	Eric L Einhorn	HLUS	590.00	1.90	1,121.00	Diligence related to claim objections (1.1); summarize claims objections for J. Beck (.6); email correspondence with J. Beck regarding claim objections (.1); email correspondence with Ernst Young and C. Bryant regarding third party vendor (.1)
03/11/19	Christopher R. Bryant	HLUS	935.00	0.70	654.50	Correspondence with E. Einhorn regarding claim

- 32 -

Orexigen Therapeutics, Inc.	Date	April 22, 2019
	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**o8 - Claims Administration and Objections**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						objections (.2); review response from D. Demko to OHSU claim query and transmit to OHSU (.4); correspondence with J. Beck regarding OHSU query (.1)
03/11/19	Eric L Einhorn	HLUS	590.00	0.70	413.00	Revise claim objections based on Ernst Young feedback (.7)
03/12/19	Christopher R. Bryant	HLUS	935.00	0.30	280.50	Review correspondence from OSHU and D. Demko regarding claim notice and respond to OSHU (.3)
03/12/19	Eric L Einhorn	HLUS	590.00	1.70	1,003.00	Email correspondence with counsel for Young and Rubicam regarding omnibus hearing date (.2); summarize complaint for C. Bryant and committee counsel (.9); email correspondence with C. Bryant regarding complaint summary (.2); attention to shareholder's claim and underlying litigation (.4)
03/13/19	Christopher R. Bryant	HLUS	935.00	0.60	561.00	Review potential claim objection recommendations, consider same and correspondence with J. Beck regarding same (.6)
03/13/19	John D Beck	HLUS	895.00	4.70	4,206.50	Review and analyze internal claims register chart and underlying proofs of claim for potential objections in advance of plan filing and summarize thoughts regarding same to team (4.4); discuss claims objections with E. Einhorn (.3)
03/13/19	Eric L Einhorn	HLUS	590.00	0.90	531.00	Email correspondence with C. Bryant, J. Beck and S.

- 33 -

Orexigen Therapeutics, Inc.	Date	April 22, 2019
	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**o8 - Claims Administration and Objections**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						Feener regarding claims register (.2); email correspondence with C. Bryant, J. Beck and S. Feener regarding claim objections (.1); attention to claims register (.3); conference with J. Beck regarding claim objections (.3)
03/13/19	Ronald Cappiello	HLUS	415.00	0.70	290.50	Assist S. Feener with request to pull claims and email copies of same to him (.7)
03/14/19	Christopher R. Bryant	HLUS	935.00	3.20	2,992.00	Emails with Hogan Lovells team regarding claim objections (.4); review of claims with respect to voting and substantive objections (2.8)
03/14/19	Eric L Einhorn	HLUS	590.00	1.50	885.00	Review and revise claim objections (.9); email correspondence with C. Bryant and J. Beck regarding claim objections (.1); further review and revise claim objections (.5)
03/15/19	John D Beck	HLUS	895.00	2.70	2,416.50	Review and revise omnibus objections for late filed claims, amended and superseded claims and no liability claims (2.7)
03/15/19	Eric L Einhorn	HLUS	590.00	1.40	826.00	Call with C. Bryant, J. Beck, and S. Feener regarding claim objections, disclosure hearing, adversary complaints and responses to disclosure hearing (1.4)
03/17/19	John D Beck	HLUS	895.00	3.20	2,864.00	Email correspondence with E. Einhorn and C. Bryant regarding omnibus objections (.2); review revisions to same circulated by E. Einhorn (3.0)

- 34 -

Orexigen Therapeutics, Inc.

Date April 22, 2019  
 Invoice No 20600019305  
 Our Ref 045803.000019

Chapter 11

**o8 - Claims Administration and Objections**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/17/19	Eric L Einhorn	HLUS	590.00	0.80	472.00	Revise claim objections based on J. Beck's comments (.8)
03/19/19	Christopher R. Bryant	HLUS	935.00	1.10	1,028.50	Review draft objections and provide comments (1.1)
03/19/19	John D Beck	HLUS	895.00	0.40	358.00	Review and consider revised 4th and 5th omnibus objections circulated by E. Einhorn (.4)
03/19/19	Eric L Einhorn	HLUS	590.00	1.50	885.00	Conference with C. Bryant regarding claim objections (.2); review and revise claim objections per C. Bryant's comments (1.3)
03/20/19	Christopher R. Bryant	HLUS	935.00	0.40	374.00	Correspondence with J. Beck and E. Einhorn regarding edits to claims objection (.4)
03/20/19	Eric L Einhorn	HLUS	590.00	1.80	1,062.00	Review and revise claim objections (1.8)
03/21/19	Eric L Einhorn	HLUS	590.00	0.20	118.00	Email correspondence with Ernst Young, local counsel, client, C. Bryant and J. Beck regarding claim objections (.2)
03/23/19	Christopher R. Bryant	HLUS	935.00	0.40	374.00	Review revised claim objections (.4)
03/25/19	Christopher R. Bryant	HLUS	935.00	0.10	93.50	Correspondence with J. Beck and E. Einhorn regarding claims objections (.1)
03/28/19	Christopher R. Bryant	HLUS	935.00	0.30	280.50	Call with E. Einhorn and emails with MNAT and E. Einhorn regarding claims objections (.3)
03/28/19	Eric L Einhorn	HLUS	590.00	0.60	354.00	Email correspondence with C. Bryant, J. Beck and S. Feener regarding claim objections (.1); review and revise claim objections (.5)



- 35 -

Orexigen Therapeutics, Inc.

Date April 22, 2019

Invoice No 20600019305

Our Ref 045803.000019

Chapter 11

**o8 - Claims Administration and Objections**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/29/19	Christopher R. Bryant	HLUS	935.00	0.30	280.50	Correspondence with M. Giughiano regarding claim objections (.2); correspondence with E. Einhorn claim objections (.1)
03/31/19	Christopher R. Bryant	HLUS	935.00	0.20	187.00	Correspondence with E. Einhorn regarding Claims objections (.2)
<b>Subtotal</b>				<b>51.80</b>	<b>38,320.50</b>	

**10 - Case Administration**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/04/19	Christopher R. Bryant	HLUS	935.00	0.60	561.00	Participate on weekly call with T. Lynch, Ernst & Young team and Hogan Lovells team (.6)
03/04/19	John D Beck	HLUS	895.00	0.50	447.50	Weekly status call with EY and T. Lynch regarding open items and filing of plan and disclosure statement (.5)
03/04/19	Eric L Einhorn	HLUS	590.00	0.60	354.00	Call with client, Ernst Young, local counsel, C. Bryant, J. Beck and S. Feener regarding outstanding items (.6)
03/05/19	Christopher R. Bryant	HLUS	935.00	0.40	374.00	Correspondence with T. Lynch and J. Beck regarding litigation holds (.4)
03/06/19	John D Beck	HLUS	895.00	0.10	89.50	Discuss scheduling with E. Einhorn (.1)
03/06/19	Ronald Cappiello	HLUS	415.00	0.60	249.00	Receive/review scheduling order related to the Plan and Confirmation (.1); Calendar Disclosure Statement hearing date, objection deadline and confirmation hearing date/time (.3); Monitor docket updates in Orexigen case (.2)

- 36 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**10 - Case Administration**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/07/19	Christopher R. Bryant	HLUS	935.00	0.40	374.00	Attention to case calendar and next steps in plan process and correspondence with S. Feener regarding same (.4)
03/07/19	Ronald Cappiello	HLUS	415.00	1.00	415.00	Receive/review request from S. Feener to calendar hearing date, objection deadline for Joint Procedures Motion and to calendar hearing on Plan Confirmation (.1); Calendar all dates and send calendar reminders to attorney team (.4); Receive request from J. Beck for copy of Exhibit 4 to D.I. 231 search/retrieval pleading and copy out exhibit 4 and email copy to J.Beck (.3); Assist J. Beck with search/retrieval and submission of copies of McKesson related stipulations (.2)
03/11/19	Christopher R. Bryant	HLUS	935.00	0.30	280.50	Correspondence with E. Einhorn regarding hearing and scheduling (.3)
03/11/19	Sean A Feener	HLUS	590.00	0.50	295.00	Weekly update call with client and professionals (.5)
03/12/19	Ronald Cappiello	HLUS	415.00	0.30	124.50	Receive/review email concerning 4-17-19 Omnibus Hearing date (.1); calendar same and send calendar reminder to attorney team (.2)
03/18/19	Christopher R. Bryant	HLUS	935.00	0.50	467.50	Participate on weekly all-hands call with T. Lynch, Ernst & Young and HL teams (.5)
03/18/19	John D Beck	HLUS	895.00	0.40	358.00	Weekly status call with Hogan and Ernst & Young teams
03/18/19	Eric L Einhorn	HLUS	590.00	0.50	295.00	Call with Ernst Young,

- 37 -

Orexigen Therapeutics, Inc.	Date	April 22, 2019
	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**10 - Case Administration**

Date	Name	LLP	Rate	Hours	Amount	Narrative
						client, C. Bryant, J. Beck and S. Feener regarding outstanding items (.5)
03/18/19	Sean A Feener	HLUS	590.00	0.90	531.00	Weekly update call (.7); related preparation and follow-up (.2)
<b>Subtotal</b>				<b>7.60</b>	<b>5,215.50</b>	

**17 - Monthly Fee Statements and Interim/Final Fee Applications (H**

Date	Name	LLP	Rate	Hours	Amount	Narrative
03/04/19	Ronald Cappiello	HLUS	415.00	1.80	747.00	Review and mark edits to February 2019 pro forma billing report for compliance (1.5); Receive/review email from C. Donoho approving January 2019 Monthly Fee Statement pleading (.1); compile Exhibit A-Invoice, cost detail chart and LEDES data file in email along with draft Monthly Fee Statement pleadings for January 2019 to T. Mann/M. Maddox at MNAT for transmittal to client for approval (.2)
03/05/19	John D Beck	HLUS	895.00	1.50	1,342.50	Review and revise February invoice (1.5)
03/10/19	Ronald Cappiello	HLUS	415.00	0.50	207.50	Set up 1st draft of February 2019 Monthly Fee Statement pleading (.5)
03/14/19	Christopher R. Donoho	HLUS	1,375.00	0.60	825.00	Review and approve 12th fee application (.6)
03/14/19	John D Beck	HLUS	895.00	0.80	716.00	Review and revise February fee application (.8)
03/14/19	Ronald Cappiello	HLUS	415.00	2.10	871.50	Receive/review finalized February 2019 invoice (.1); Update draft Monthly Fee Statement pleading (.3); coordinate with Billing Dept. for detail cost report

- 38 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**17 - Monthly Fee Statements and Interim/Final Fee Applications (H**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						and LEDES data file for invoice (.1); Set up invoice for filing (.1); receive/review cost detail chart (.1); Set up email to T. Mann (MNAT) for attaching fee statement, invoice and LEDES data file for forwarding to client for approval and e-filing thereafter (.1); Work on set up of excel spreadsheet for 4th interim fee and expense calculations (.4); Review Declaration 2018 and Jan-Feb 2019 Fee Statements and start compiling hours, fees of timekeepers and perform calculations therefor (.9)
03/15/19	Ronald Cappiello	HLUS	415.00	2.40	996.00	Review December, January and February invoices and fee statements (.4); continue calculations and work on excel charts for 4th interim fee application (2.0)
03/22/19	Ronald Cappiello	HLUS	415.00	0.90	373.50	Continue review of December thru February fee statements and calculations for 4th interim fee application (.9)
03/25/19	Ronald Cappiello	HLUS	415.00	4.20	1,743.00	Review Declaration 2018 through Feb. 2019 monthly invoices and fee statements (.3); continue calculations for timekeepers, project codes for Orexigen 4th interim fee application (3.6); coordinate with Document Services for improvements to Timekeeper Cumulative Chart (.3)
03/26/19	Ronald Cappiello	HLUS	415.00	4.40	1,826.00	Continue and complete calculations for Project Code and Expense

- 39 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**17 - Monthly Fee Statements and Interim/Final Fee Applications (H**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
						Summary charts for Hogan Lovells' 4th interim fee period covering December 2018 thru February 2019 (2.2); Coordinate with pricing dept. for updates to comparables chart for fee application (.3); draft text and charts to fee application and review monthly fee statements in connection therewith (1.1); send email to J. Beck with draft of fee application, copies of fee statements and Master A/R excel (.2); work on calculations of payments for various items on the fee application cover sheet (.4); Email exchanges with M. Maddox, J. Beck. C. Donoho regarding setting next fee hearing (.2)
03/27/19	Ronald Cappiello	HLUS	415.00	0.80	332.00	Coordinate with Pricing Department personnel for preparation and calculations of comparable chart for Hogan's 4th interim fee application (.3); receive/review email from M. Maddox confirming 5-1-19 10:00 a.m. fee hearing (.1); calendar hear date/time and deadline date by which to file fee applications and send calendar reminders to attorneys regarding same (.4)
03/28/19	Ronald Cappiello	HLUS	415.00	0.20	83.00	Email exchanges with Pricing Department personnel for assistance in updating comparables chart (.2)
<b>Subtotal</b>				<b>20.20</b>	<b>10,063.00</b>	

- 40 -

Orexigen Therapeutics, Inc.	Date	April 22, 2019
	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**20 - Non-Working Travel**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/26/19	John D Beck	HLUS	895.00	2.00	1,790.00	Non-working travel to Delaware for disclosure statement hearing (2.0)
03/27/19	John D Beck	HLUS	895.00	2.00	1,790.00	Non-working travel back to NY from Delaware for disclosure statement hearing (2.0)
03/27/19	Eric L Einhorn	HLUS	590.00	3.60	2,124.00	Travel to Delaware (1.5); travel to New York (2.1)
03/27/19	Sean A Feener	HLUS	590.00	5.00	2,950.00	Non-working travel to/from Delaware for Disclosure Statement hearing (5.)
				<b>Subtotal</b>	<b>12.60</b>	<b>8,654.00</b>

**24 - Asset Dispositions/363 Sales**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/11/19	Christopher R. Bryant	HLUS	935.00	0.40	374.00	Review Nalprop letter and transmit to B. Murphy with cover note (.4)
03/12/19	Christopher R. Bryant	HLUS	935.00	1.10	1,028.50	Review correspondence from D. Demko regarding Takeda and scan documents (.9); various emails regarding call with Nalpropion regarding Patheon (.2)
03/21/19	Christopher R. Bryant	HLUS	935.00	0.40	374.00	Call with T. Lynch regarding Nalpropion hold back matters and follow with B. Murphy regarding same (.4)
03/23/19	Christopher R. Bryant	HLUS	935.00	0.20	187.00	Follow-up with T. Lynch and B Murphy regarding 401(k) payments and Nalpropion settlement talks (.2)
03/28/19	Christopher R. Bryant	HLUS	935.00	0.10	93.50	Correspondence with T. Lynch regarding holdbacks (.1)
				<b>Subtotal</b>	<b>2.20</b>	<b>2,057.00</b>

- 41 -

Orexigen Therapeutics, Inc.

Date April 22, 2019  
 Invoice No 20600019305  
 Our Ref 045803.000019

Chapter 11

**25 - Automatic Stay Matters**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/01/19	Christopher R. Bryant	HLUS	935.00	0.60	561.00	Correspondence with A. Remming regarding stay issues and consideration of same (.6);
03/02/19	Christopher R. Bryant	HLUS	935.00	0.40	374.00	Correspondence and call with E. Einhorn regarding stay matters (.4)
03/02/19	Eric L Einhorn	HLUS	590.00	4.90	2,891.00	Research related to the automatic stay (2.6); conference with C. Bryant regarding research (.2); further research section 362 of the bankruptcy code and the automatic stay (2.1)
03/03/19	Christopher R. Bryant	HLUS	935.00	0.50	467.50	Review stay research results from E. Einhorn and reply (.5)
03/03/19	Christopher R. Bryant	HLUS	935.00	0.20	187.00	Correspondence with Cooley regarding automatic stay issues (.2)
03/03/19	John D Beck	HLUS	895.00	0.30	268.50	Email correspondence with C. Bryant and E. Einhorn regarding stay (.3)
03/03/19	Eric L Einhorn	HLUS	590.00	0.90	531.00	Summarize research relating to the automatic stay (.7); email correspondence with C. Bryant, J. Beck and S. Feener regarding automatic stay research (.2)
03/11/19	Christopher R. Bryant	HLUS	935.00	0.30	280.50	Correspondence with S. Feener and E. Einhorn regarding stay research (.3)
03/13/19	Christopher R. Bryant	HLUS	935.00	2.10	1,963.50	Revise materials regarding stay, perform related research and provide summary to Irell regarding same (2.1)
03/25/19	Christopher R. Bryant	HLUS	935.00	9.70	9,069.50	Numerous emails with J. Reisner, T. Lynch, J. Lombard, MNAT and J. Beck regarding disclosure

Date	April 22, 2019
Invoice No	20600019305
Our Ref	045803.000019

## 25 - Automatic Stay Matters

Date	Name	LLP	Rate	Hours	Amount	Narrative
						statement hearing and open plan issues and agenda (.9); further review of revised plan and disclosure statement and revise same (.4); correspondence from U.S. Bank regarding escrow agreement (.1); call with J. Reisner regarding plan and document retention issues (.3); draft language for plan and transmit to J. Reisner for review (.3); call with B. Murphy regarding plan and other matters (.2); correspondence with B. Brownstein regarding objection and hearing (.1); revise plan and disclosure statement and circulate to Lowenstein for review with cover note (.9); correspondence and call with J. Lombard regarding document retention (.2); revise note register notice and circulate (.6); review U.S. Bank fee chart and circulate (.2); correspondence with J. Reisner regarding open plan points (.2); attention to note register distribution and draft and preparation of individual notices, etc. (4.8); correspondence with J. Lombard regarding stay (.1); conference with S. Friedman regarding tax forms and correspondence with B. Feder and B. Murphy regarding same (.3); follow-up with Lowenstein regarding plan and disclosure statement (.1)
				<b>Subtotal</b>	<b>19.90</b>	<b>16,593.50</b>



- 43 -

Orexigen Therapeutics, Inc.

Date April 22, 2019

Invoice No 20600019305

Our Ref 045803.000019

Chapter 11

**26 - Insurance Matters**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/07/19	John D Beck	HLUS	895.00	0.20	179.00	Call with J. Lombard regarding insurance coverage for Ninth Circuit litigation (.2)
03/11/19	Pieter Van Tol	HLUS	1,195.00	0.50	597.50	Telephone conference with J. Lombard and Creditors Committee regarding insurance and litigation issues (.5)
03/11/19	John D Beck	HLUS	895.00	0.40	358.00	Email correspondence with C. Bryant regarding automatic stay, insurance issues and subordination (.4)
03/12/19	Pieter Van Tol	HLUS	1,195.00	0.40	478.00	E-mails on insurance issues (.4)
03/18/19	John D Beck	HLUS	895.00	0.20	179.00	Revise Certification of Counsel regarding payment of insurance costs to former directors and officers (.2)
				<b>Subtotal</b>	<b>1.70</b>	<b>1,791.50</b>

**27 - Vendor/Supplier Matters**

<b>Date</b>	<b>Name</b>	<b>LLP</b>	<b>Rate</b>	<b>Hours</b>	<b>Amount</b>	<b>Narrative</b>
03/07/19	Sean A Feener	HLUS	590.00	0.30	177.00	Call with Cooley regarding insurance issues (.3)
				<b>Subtotal</b>	<b>0.30</b>	<b>177.00</b>

<b>Total Professional Services</b>	<b>401.20</b>	<b>USD 323,344.50</b>
<b>Less Non-Working Travel</b>		<b>(4,327.00)</b>
<b>Total Professional Services Charged</b>		<b>USD 319,017.50</b>

- 44 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**Summary**

<b>Timekeeper Name</b>	<b>Hours</b>	<b>Rate</b>	<b>Fees</b>
Christopher R. Donoho	10.90	1,375.00	14,987.50
Pieter Van Tol	1.50	1,195.00	1,792.50
Scott Friedman	8.20	1,175.00	9,635.00
Christopher R. Bryant	159.30	935.00	148,945.50
John D Beck	67.90	895.00	60,770.50
Catherine Chen	4.10	730.00	2,993.00
Sean A Feener	41.80	590.00	24,662.00
Eric L Einhorn	81.20	590.00	47,908.00
Jennifer Lee	6.40	530.00	3,392.00
Ronald Cappiello	19.90	415.00	8,258.50
<b>Total Professional Services</b>	<b>401.20</b>		<b>USD 323,344.50</b>
<b>Less Non-Working Travel</b>			<b>(4,327.00)</b>
<b>Total Professional Services Charged</b>			<b>USD 319,017.50</b>

- 45 -

Orexigen Therapeutics, Inc.

Date	April 22, 2019
Invoice No	20600019305
Our Ref	045803.000019

Chapter 11

**Summary**

<b>Task</b>	<b>Task Code Description</b>	<b>Hours</b>	<b>Fees</b>
03	Hearings	29.90	21,267.01
04	DIP or Exit Financing	1.10	1,028.50
05	Litigation:Contested Matters, Adv. Proceedings, other Litigation	27.10	19,776.50
07	Plan and Disclosure Statement	226.80	198,400.49
08	Claims Administration and Objections	51.80	38,320.50
10	Case Administration	7.60	5,215.50
17	Monthly Fee Statements and Interim/Final Fee Applications (H	20.20	10,063.00
20	Non-Working Travel	12.60	8,654.00
24	Asset Dispositions/363 Sales	2.20	2,057.00
25	Automatic Stay Matters	19.90	16,593.50
26	Insurance Matters	1.70	1,791.50
27	Vendor/Supplier Matters	0.30	177.00
<b>Total Professional Services</b>		<b>401.20</b>	<b>USD 323,344.50</b>

- 46 -

	Date	April 22, 2019
Orexigen Therapeutics, Inc.	Invoice No	20600019305
	Our Ref	045803.000019

Chapter 11

**Disbursement and Charges**

<b>Description</b>	<b>Amount</b>
Hospitality	40.05
Car Service	322.94
Taxi	29.65
Meals	44.40
Computer Research - Westlaw	957.29
EPIQ Other Case Specified Data Services	32.00
Word Processing	168.75
<b>Total for Other Charges</b>	<b><u>USD 1,595.08</u></b>

Date	April 22, 2019
Invoice No	20600019305
Our Ref	045803.000019

Paid-in-full invoices and corresponding payments are not shown below.  
This summary reflects payments received through April 22, 2019  
This statement includes the current invoice.

Invoice No.	Date	Fees	Other Charges	Total	Payments	Date Last Payment	Balance USD
20600010846	09/18/18	136,960.00	1,836.45	138,796.45	129,638.95	2018-10-26	9,157.50
20600015888	01/14/19	45,253.07	437.39	45,690.46	36,639.79	2019-02-11	9,050.67
20600017091	02/27/19	180,802.50	927.42	181,729.92	145,569.42	2019-04-08	36,160.50
20600017673	03/14/19	156,360.50	409.03	156,769.53	0.00		156,769.53
20600019305	04/22/19	319,017.50	1,595.08	320,612.58	0.00		320,612.58
Outstanding Invoices:							531,750.78